Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes

Experimental Diabesity Research

Volumn 2007, Issue , 2007, Pages

  Canning, Paul ^a   Glenn, Josephine V ^a   Hsu, Daniel K ^a   Liu, Fu Tong ^a   Gardiner, Tom A ^a   Stitt, Alan W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; EVANS BLUE; GALECTIN 3; GLUCOSE; MESSENGER RNA; OCCLUDIN; PYRIDOXAMINE; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MALE; MEMBRANE DAMAGE; MICROVASCULATURE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA; RETINA BLOOD VESSEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIGHT JUNCTION; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; MOUSE MUTANT; POLYMERASE CHAIN REACTION; TIME;

ANIMALS; BLOOD-RETINAL BARRIER; DIABETES MELLITUS, EXPERIMENTAL; GALECTIN 3; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; RETINA; RNA, MESSENGER; TIGHT JUNCTIONS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247354628     PISSN: 15438600     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2007/51837     Document Type: Article

References (57)

1. R. J. Antcliff J. Marshall The pathogenesis of edema in diabetic maculopathy Seminars in Ophthalmology 14 4 1999 223-232
2. C. Engler B. Krogsaa H. Lund-Andersen Blood-retina barrier permeability and its relation to the progression of diabetic retinopathy in type 1 diabetes. An 8-year follow-up study Graefe's Archive for Clinical and Experimental Ophthalmology 229 5 1991 442-446
3. B. Sander M. Larsen C. Engler Diabetic macular oedema: A comparison of vitreous fluorometry, angiography, and retinopathy British Journal of Ophthalmology 86 3 2002 316-320
4. G. L. Trick gltrick1@aol.com J. Liggett J. Levy Dynamic contrast enhanced MRI in patients with diabetic macular edema: Initial results Experimental Eye Research 81 1 2005 97-102
5. M. S. Roy M. J. Podgor P. Bungay G. Grunberger J. Carl D. Ellis Posterior vitreous fluorophotometry in diabetic patients with minimal or no retinopathy Retina 7 3 1987 170-176
6. J. Cunha-Vaz C. Lobo J. C. Sousa B. Oliveiros E. Leite J. R. Faria de Abreu Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes: A 7-year prospective follow-up study Graefe's Archive for Clinical and Experimental Ophthalmology 236 4 1998 264-268
7. A. B. El-Remessy M. A. Behzadian G. Abou-Mohamed T. Franklin R. W. Caldwell R. B. Caldwell rcaldwel@mail.mcg.edu Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor American Journal of Pathology 162 6 2003 1995-2004
8. T. Qaum Q. Xu A. M. Joussen VEGF-initiated blood-retinal barrier breakdown in early diabetes Investigative Ophthalmology and Visual Science 42 10 2001 2408-2413
9. R. H. Amin R. N. Frank A. Kennedy D. Eliott J. E. Puklin G. W. Abrams Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy Investigative Ophthalmology and Visual Science 38 1 1997 36-47
10. D. A. Antonetti dantonetti@psu.edu A. J. Barber L. A. Hollinger E. B. Wolpert T. W. Gardner Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors Journal of Biological Chemistry 274 33 1999 23463-23467
11. A. J. Barber D. A. Antonetti dantonetti@psu.edu Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats Investigative Ophthalmology and Visual Science 44 12 2003 5410-5416
12. S. Ishida T. Usui K. Yamashiro VEGF164 is proinflammatory in the diabetic retina Investigative Ophthalmology and Visual Science 44 5 2003 2155-2162
13. L. P. Aiello S.-E. Bursell A. Clermont Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor Diabetes 46 9 1997 1473-1480
14. R. Rota C. Chiavaroli R. P. Garay garayperso@aol.com P. Hannaert Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats European Journal of Pharmacology 495 2-3 2004 217-224
15. A. K. H. Cheung M. K. L. Fung A. C. Y. Lo Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice Diabetes 54 11 2005 3119-3125
16. I. G. Obrosova iobrosso@umich.edu A. G. Minchenko R. Vasupuram Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats Diabetes 52 3 2003 864-871
17. S. R. Thorpe J. W. Baynes baynes@mail.chem.sc.edu Maillard reaction products in tissue proteins: New products and new perspectives Amino Acids 25 3-4 2003 275-281
18. H.-P. Hammes A. Alt T. Niwa Differential accumulation of advanced glycation end products in the course of diabetic retinopathy Diabetologia 42 6 1999 728-736
19. N. Karachalias R. Babaei-Jadidi N. Ahmed P. J. Thornalley thorp@essex.ac.uk Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats Biochemical Society Transactions 31, part 6 2003 1423-1425
20. A. W. Stitt Y. M. Li T. A. Gardiner R. Bucala D. B. Archer H. Vlassara Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats American Journal of Pathology 150 2 1997 523-531
21. A. W. Stitt T. Bhaduri C. B. T. McMullen T. A. Gardiner D. B. Archer Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats Molecular Cell Biology Research Communications 3 6 2000 380-388
22. A. W. Stitt T. A. Gardiner N. L. Anderson The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes Diabetes 51 9 2002 2826-2832
23. T. A. Gardiner H. R. Anderson A. W. Stitt Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes Journal of Pathology 201 2 2003 328-333
24. A. Bierhaus M. A. Hofmann R. Ziegler P. P. Nawroth AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept Cardiovascular Research 37 3 1998 586-600
25. A. M. Schmidt S. D. Yan S. F. Yan D. M. Stern The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses Journal of Clinical Investigation 108 7 2001 949-955
26. A. W. Stitt a.stitt@qub.ac.uk C. McGoldrick A. Rice-McCaldin Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3 Diabetes 54 3 2005 785-794
27. M. Lu M. Kuroki S. Amano Advanced glycation end products increase retinal vascular endothelial growth factor expression Journal of Clinical Investigation 101 6 1998 1219-1224
28. S.-I. Yamagishi H. Yonekura Y. Yamamoto Advanced glycation end products-driven angiogenesis in vitro: Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor Journal of Biological Chemistry 272 13 1997 8723-8730
29. S. McFarlane J. V. Glenn A. M. Lichanska D. A. C. Simpson A. W. Stitt a.stitt@qub.ac.uk Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium British Journal of Ophthalmology 89 1 2005 107-112
30. K. Otero F. Martínez A. Beltrán Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells Biochemical Journal 359, part 3 2001 567-574
31. G. Leto F. Pricci L. Amadio Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: Role of advanced non-enzymatic glycation and polyol pathway activation Diabetes/ Metabolism Research and Reviews 17 6 2001 448-458
32. T. C. B. Moore t.moore@ulster.ac.uk J. E. Moore Y. Kaji The role of advanced glycation end products in retinal microvascular leukostasis Investigative Ophthalmology and Visual Science 44 10 2003 4457-4464
33. D. K. Hsu R.-Y. Yang Z. Pan Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses American Journal of Pathology 156 3 2000 1073-1083
34. O. T. Cox D. A. C. Simpson A. W. Stitt a.stitt@qub.ac.uk T. A. Gardiner Sources of PDGF expression in murine retina and the effect of short-term diabetes Molecular Vision 10 2003 9 665-672
35. B. Brankin brenda.brankin@ucd.ie M. Campbell P. Canning T. A. Gardiner A. W. Stitt Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium Experimental Eye Research 81 1 2005 22-31
36. D. A. Simpson S. Feeney C. Boyle A. W. Stitt Retinal VEGF mRNA measured by SYBR green I fluorescence: A versatile approach to quantitative PCR Molecular Vision 6 2000 178-183
37. A. M. Joussen V. Poulaki N. Mitsiades Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression The FASEB Journal 16 3 2002 438-440
38. A. M. Joussen V. Poulaki W. Qin Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo American Journal of Pathology 160 2 2002 501-509
39. A. W. Stitt a.stitt@qub.ac.uk T. M. Curtis Advanced glycation and retinal pathology during diabetes Pharmacological Reports 57 supplement 2005 156-168
40. P. S. Padayatti C. Jiang M. A. Glomb K. Uchida R. H. Nagaraj High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells Current Eye Research 23 2 2001 106-115
41. D. Yao T. Taguchi T. Matsumura Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription Cell 124 2 2006 275-286
42. I. Giardino D. Edelstein M. Brownlee Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes Journal of Clinical Investigation 94 1 1994 110-117
43. A. W. Stitt U. Chakravarthy D. B. Archer T. A. Gardiner Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation Diabetologia 38 11 1995 1271-1275
44. D. S. Fosmark dag.fosmark@medisin.uio.no P. A. Torjesen B. K. Kilhovd Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus Metabolism 55 2 2006 232-236
45. D. J. McKenna J. Nelson A. W. Stitt a.stitt@qub.ac.uk Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells Life Sciences 68 24 2001 2695-2703
46. H.-P. Hammes D. Strodter A. Weiss R. G. Bretzel K. Federlin M. Brownlee Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model Diabetologia 38 6 1995 656-660
47. N. L. Alderson M. E. Chachich N. N. Youssef The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats Kidney International 63 6 2003 2123-2133
48. R. H. Nagaraj P. Sarkar A. Mally K. M. Biemel M. O. Lederer P. S. Padayatti Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: Characterization of a major product from the reaction of pyridoxamine and methylglyoxal Archives of Biochemistry and Biophysics 402 1 2002 110-119
49. C. Treins S. Giorgetti-Peraldi peraldis@unice.fr J. Murdaca E. Van Obberghen Regulation of vascular endothelial growth factor expression by advanced glycation end products Journal of Biological Chemistry 276 47 2001 43836-43841
50. J. Dumic jdumic@pharma.hr S. Dabelic M. Flögel Galectin-3: An open-ended story Biochimica et Biophysica Acta (BBA)-General Subjects 1760 4 2006 616-635
51. H. Vlassara R. Bucala L. Striker Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging Laboratory Investigation 70 2 1994 138-151
52. W. Zhu H. Sano R. Nagai K. Fukuhara A. Miyazaki S. Horiuchi The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins Biochemical and Biophysical Research Communications 280 4 2001 1183-1188
53. G. Pugliese demfound@tin.it F. Pricci G. Leto The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression Diabetes 49 7 2000 1249-1257
54. G. Pugliese F. Pricci C. Iacobini Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice The FASEB Journal 15 13 2001 2471-2479
55. F.-T. Liu R. J. Patterson J. L. Wang Intracellular functions of galectins Biochimica et Biophysica Acta (BBA)-General Subjects 1572 2-3 2002 263-273
56. C. Colnot M.-A. Ripoche G. Milon X. Montagutelli P. R. Crocker F. Poirier Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice Immunology 94 3 1998 290-296
57. H. Sano D. K. Hsu J. R. Apgar Critical role of galectin-3 in phagocytosis by macrophages Journal of Clinical Investigation 112 3 2003 389-397